Brickell Biotech (BBI) will release quarterly earnings on Thursday

Brickell Biotech, Inc. (NASDAQ: BBI) is expected to announce quarterly sales of $ 1.23 million


According to Zacks, brokers expect Brickell Biotech, Inc. (NASDAQ: BBI – Get Rating) to record sales of $ 1.23 million for the current quarter. Three analysts made estimates for Brickell Biotech’s earnings, with estimates ranging from $ 110,000.00 to $ 3.08 million. Brickell Biotech posted sales of $ 150,000.00 during the same quarter last year, suggesting a positive year-over-year growth rate of 720%. The company is expected to release its next quarterly earnings results on Monday January 1st.

On average, analysts expect Brickell Biotech to report full-year sales of $ 2.43 million for the current year, with estimates ranging from $ 480,000.00 to $ 4.30 million. For the next financial year, analysts expect the company to record sales of $ 11.08 million, with estimates ranging from $ 5.35 million to $ 16.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms following Brickell Biotech.

Brickell Biotech (NASDAQ: BBI – Get Rating) last released its earnings results on Thursday, May 12. The company reported ($ 0.08) earnings per share for the quarter, missing analyst consensus estimates of ($ 0.06) of ($ 0.02). Brickell Biotech had a negative net margin of 9,770.79% and a negative return on equity of 163.84%. During the same quarter last year, the company reported earnings per share ($ 0.15).

A number of research firms have recently weighed in on BBI. Zacks Investment Research cut the shares of Brickell Biotech from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10. Lake Street Capital cut shares of Brickell Biotech from a “buy” rating to a “hold” rating in a research note Friday. HC Wainwright began hedging the shares of Brickell Biotech in a research note on Tuesday, Jan.18. They have set a “buy” rating and a $ 2.00 price target on the stock. Finally, William Blair began hedging on the shares of Brickell Biotech in a research note on Tuesday, March 8. They have established an “outperform” rating on the stock.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its position in the shares of Brickell Biotech by 69.2% during the third quarter. BlackRock Inc. now owns 63,544 shares of the company worth $ 46,000 after purchasing an additional 25,985 shares in the last quarter. Morgan Stanley raised its position in the shares of Brickell Biotech by 142.0% during the first quarter. Morgan Stanley now owns 75,404 shares of the company worth $ 82,000 after buying an additional 44,248 shares in the last quarter. Geode Capital Management LLC increased its position in the shares of Brickell Biotech by 11.4% during the third quarter. Geode Capital Management LLC now owns 627,294 shares in the company worth $ 451,000 after buying an additional 63,982 shares in the last quarter. Two Sigma Investments LP increased its position in the shares of Brickell Biotech by 277.2% during the third quarter. Two Sigma Investments LP now owns 90,085 shares in the company worth $ 65,000 after buying another 66,200 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Brickell Biotech in the second quarter valued at approximately $ 76,000. Institutional investors own 14.99% of the company’s shares.

NASDAQ BBI opened at $ 0.19 on Friday. The stock has a market capitalization of $ 22.20 million, a P / E ratio of -0.40 and a beta of 0.12. The company’s 50-day simple moving average is $ 0.26 and its 200-day simple moving average is $ 0.27. Brickell Biotech has a twelve-month low of $ 0.19 and a twelve-month high of $ 1.04.

About Brickell Biotech (Get evaluation)

Brickell Biotech, Inc, a clinical stage pharmaceutical company, is engaged in the development of various prescription drugs for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironio bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent interferon gene inhibitor stimulator for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.

Featured stories

Get a Free Copy of the Zacks Research Report on Brickell Biotech (BBI)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

History and Earnings Estimates for Brickell Biotech (NASDAQ: BBI)



Get news and ratings for Brickell Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Brickell Biotech and related companies with MarketBeat.com’s FREE daily newsletter.

.

Leave a Comment

Your email address will not be published.